scholarly journals Long-term efficacy of infliximab on background vascular leakage in patients with Behçet’s disease

Eye ◽  
2014 ◽  
Vol 28 (9) ◽  
pp. 1100-1106 ◽  
Author(s):  
H Keino ◽  
A A Okada ◽  
T Watanabe ◽  
W Taki
Keyword(s):  
Behçet’S Disease ◽  
Behcet’S Disease ◽  
Behçet's Disease ◽  
Vascular Leakage ◽  
Behcet's Disease ◽  
Term Efficacy

scholarly journals Long-term efficacy and safety of anakinra in a patient with Behçet's disease and concomitant tuberculosis infection

2016 ◽  
Vol 56 (2) ◽  
pp. 218-220 ◽  
Author(s):  
Giacomo Emmi ◽  
Elena Silvestri ◽  
Danilo Squatrito ◽  
Antonio Vitale ◽  
Daniela Bacherini ◽  
...  
Keyword(s):  
Behçet’S Disease ◽  
Behcet’S Disease ◽  
Behçet's Disease ◽  
Tuberculosis Infection ◽  
Efficacy And Safety ◽  
Behcet's Disease ◽  
Term Efficacy

Long-term efficacy and safety of golimumab in the treatment of multirefractory Behçet’s disease

2017 ◽  
Vol 36 (9) ◽  
pp. 2063-2069 ◽  
Author(s):  
Antonio Vitale ◽  
Giacomo Emmi ◽  
Giuseppe Lopalco ◽  
Claudia Fabiani ◽  
Stefano Gentileschi ◽  
...  
Keyword(s):  
Behçet’S Disease ◽  
Behcet’S Disease ◽  
Behçet's Disease ◽  
Efficacy And Safety ◽  
Behcet's Disease ◽  
Term Efficacy

Long-term efficacy of early infliximab-induced remission for refractory uveoretinitis associated with Behçet’s disease

2020 ◽  
pp. bjophthalmol-2020-316892
Author(s):  
Hiroshi Keino ◽  
Takayo Watanabe ◽  
Makiko Nakayama ◽  
Yoshinori Komagata ◽  
Kazuhito Fukuoka ◽  
...  
Keyword(s):  
Behçet’S Disease ◽  
Short Duration ◽  
Behcet’S Disease ◽  
Behçet's Disease ◽  
Group Versus ◽  
Behcet's Disease ◽  
Term Efficacy ◽  
Long Duration

BackgroundTo evaluate long-term efficacy of infliximab (IFX) in refractory uveoretinitis associated with Behçet’s disease (BD) depending on uveoretinitis duration.MethodsRecords of 16 patients with BD (32 eyes) followed for >5 years after starting IFX, were retrospectively reviewed. Long-term efficacy was compared between patients with short duration (≤18 months, n=7) versus long duration (>18 months, n=9) of their uveoretinitis prior to starting IFX.ResultsThe median follow-up after starting IFX was 132 months (76–146 months). Mean frequency of attacks and the 1-year Behçet’s Disease Ocular Attack Score 24 decreased significantly over 10 years. Overall, the percentage of eyes with a best-corrected visual acuity (BCVA) ≥1.0 increased from 47% at baseline to 59% at 5 years; the percentage of eyes with a BCVA ≤0.1 was 19% at both baseline and 5 years. The frequency of ocular attacks decreased similarly in both short duration and long duration groups; however, the percentage of eyes with a BCVA ≥1.0 at 5 years was 100% in the short duration group versus 28% in the long duration group. IFX was discontinued in four patients with an excellent response to IFX therapy; all were young male patients in the short duration group with good BCVA bilaterally, and none had inflammatory recurrences over a median follow-up of 56 months off IFX.ConclusionInitiation of IFX therapy in patients with BD within 18 months of their uveoretinitis onset was more effective in maintaining good BCVA than after 18 months.

scholarly journals Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study

Rheumatology ◽  
2007 ◽  
Vol 46 (7) ◽  
pp. 1161-1164 ◽  
Author(s):  
L. Niccoli ◽  
C. Nannini ◽  
M. Benucci ◽  
D. Chindamo ◽  
E. Cassara ◽  
...  
Keyword(s):  
Behçet’S Disease ◽  
Behcet’S Disease ◽  
Behçet's Disease ◽  
Posterior Uveitis ◽  
Behcet's Disease ◽  
Follow Up Study ◽  
Term Efficacy

Long-term efficacy and safety of interferon α-2a therapy in severe refractory ophthalmic Behcet’s disease

2016 ◽  
Vol 35 (11) ◽  
pp. 2765-2769 ◽  
Author(s):  
Hadise Kavandi ◽  
Alireza Khabbazi ◽  
Sousan Kolahi ◽  
Mehrzad Hajialilo ◽  
Farid Karkon Shayan ◽  
...  
Keyword(s):  
Behçet’S Disease ◽  
Behcet’S Disease ◽  
Behçet's Disease ◽  
Interferon Α ◽  
Efficacy And Safety ◽  
Behcet's Disease ◽  
Term Efficacy

SAT0168 Long Term Efficacy and Safety of Infliximab in the Treatment of BehÇEt’S Disease

2013 ◽  
Vol 72 (Suppl 3) ◽  
pp. A638.3-A638
Author(s):  
P. Leccese ◽  
L. Latanza ◽  
A. Padula ◽  
A. Nigro ◽  
S. D’Angelo ◽  
...  
Keyword(s):  
Behçet’S Disease ◽  
Behcet’S Disease ◽  
Behçet's Disease ◽  
Efficacy And Safety ◽  
Behcet's Disease ◽  
Term Efficacy
Sign in / Sign up

Export Citation Format

Share Document